Literature DB >> 9333169

Dominant cytotoxic T lymphocyte response to the immediate-early trans-activator protein, BZLF1, in persistent type A or B Epstein-Barr virus infection.

S L Elliott1, S J Pye, C Schmidt, S M Cross, S L Silins, I S Misko.   

Abstract

Five healthy human leukocyte antigen-B8 (HLA-B8)-positive virus carriers were studied to investigate the CD8+ cytotoxic T lymphocyte (CTL) response to an HLA-B8-restricted peptide, RAKFKQLLQ, located in the Epstein-Barr virus (EBV) immediate-early trans-activator protein, BZLF1. Of the 5 virus carriers, 4 were infected with type A and 1 with type B EBV. Using limiting-dilution analysis of peripheral blood mononuclear cells, a high RAKFKQLLQ-specific CTL precursor frequency was demonstrated after specific peptide or autologous lymphoblastoid cell line stimulation in both type A and type B EBV carriers. The RAKFKQLLQ-specific CTL precursor frequencies in all 5 persons were at least as dominant as those observed with two other EBV-associated, HLA-B8-restricted latent epitopes, FLRGRAYGL and QAKWRLQTL. These findings show that healthy virus carriers maintain a high frequency of BZLF1-specific memory T cells, potentially to control virus spread from lytically infected cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9333169     DOI: 10.1086/516513

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  6 in total

1.  Crossreactive recognition of viral, self, and bacterial peptide ligands by human class I-restricted cytotoxic T lymphocyte clonotypes: implications for molecular mimicry in autoimmune disease.

Authors:  I S Misko; S M Cross; R Khanna; S L Elliott; C Schmidt; S J Pye; S L Silins
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

2.  Detailed analysis of Epstein-Barr virus-specific CD4+ and CD8+ T cell responses during infectious mononucleosis.

Authors:  J Scherrenburg; E R W A N Piriou; N M Nanlohy; D van Baarle
Journal:  Clin Exp Immunol       Date:  2008-06-28       Impact factor: 4.330

Review 3.  Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts.

Authors:  R J O'Reilly; T N Small; E Papadopoulos; K Lucas; J Lacerda; L Koulova
Journal:  Springer Semin Immunopathol       Date:  1998

4.  CD4+ and CD8+ T-cell responses to latent antigen EBNA-1 and lytic antigen BZLF-1 during persistent lymphocryptovirus infection of rhesus macaques.

Authors:  R M Leskowitz; X Y Zhou; F Villinger; M H Fogg; A Kaur; P M Lieberman; F Wang; H C Ertl
Journal:  J Virol       Date:  2013-05-22       Impact factor: 5.103

Review 5.  Progress in Research and Application of HIV-1 TAT-Derived Cell-Penetrating Peptide.

Authors:  Le Zou; Qilin Peng; Ping Wang; Boting Zhou
Journal:  J Membr Biol       Date:  2016-12-08       Impact factor: 1.843

6.  The EBV immunoevasins vIL-10 and BNLF2a protect newly infected B cells from immune recognition and elimination.

Authors:  Simon Jochum; Andreas Moosmann; Stephan Lang; Wolfgang Hammerschmidt; Reinhard Zeidler
Journal:  PLoS Pathog       Date:  2012-05-17       Impact factor: 6.823

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.